Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / B2M



This biomarker is also known as:
  • CDABP0092,
  • beta-2-microglobulin,
  • HDCMA22P,


B2M, a secreted protein belonging to the beta-2-microglobulin family, is a component of the class I major histocompatibility complex (MHC) on the surface of nearly all nucleated cells and involved in the presentation of peptide antigens to the immune system. A mutation in this gene has been shown to result in hypercatabolic hypoproteinemia. B2M is detected in serum and urine.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: B2M


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


B2M has been shown to be the target molecule of an antibody pool against SKOV3 ovarian cancer cells. Studies have also indicated that specific antibody of B2M can inhibit the growth of SKOV3. In addition, overexpression of B2M promotes the growth of SKOV3 cells in vitro.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. B2M alone was not a strong predictor.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated publications found.


Mutation Statistics

Gene Name: B2M
UniProt Accession #: P61769
Mutated Sites Count: 49
Associated Pubmed ID Count 15
CancerDO Count 18
Affected Protein Function Sites Count: 5

View in BioMuta